Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erbitux in locally advanced esophageal squamous cell carcinoma
NCT00815308Phase 2Completed
- Sponsor
- Shandong Cancer Hospital
- Start
- Jan 2009
- Primary completion
- Jul 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shandong Cancer Hospital. Started Jan 2009; status: completed.
02
Drugs
cetuximab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT00815308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00815308.